Topiramate tablet
Reading File
Finding Sources
Searching PubMed
topiramate clinical pharmacology
Reading File
Reading File
Reading File
Here is a thorough reference on Topiramate (Topamax) tablets:
Topiramate (Topamax) Tablet
Drug Class
Antiepileptic / Anticonvulsant; also used for migraine prophylaxis and weight management (in combination with phentermine as Qsymia).
Formulations
- Tablets: 25 mg, 50 mg, 100 mg, 200 mg
- Sprinkle capsules: 15 mg, 25 mg (can be swallowed whole or sprinkled on food)
Mechanisms of Action
Topiramate has multiple, distinct mechanisms (Goodman & Gilman's):
| Mechanism | Effect |
|---|---|
| State-dependent Na+ channel blockade | Reduces repetitive firing of action potentials |
| Hyperpolarizing K+ current activation | Stabilizes neuronal membranes |
| GABA-A potentiation | Enhances inhibitory neurotransmission |
| AMPA/kainate (GluA, GluK) antagonism | Reduces excitatory glutamatergic transmission |
| Carbonic anhydrase inhibition (CA-II, CA-IV) | Weak inhibition; contributes to metabolic acidosis and nephrolithiasis risk |
Pharmacokinetics
| Parameter | Value |
|---|---|
| Oral bioavailability | ~80% |
| Protein binding | 10-20% (low) |
| Volume of distribution | ~0.8 L/kg |
| Renal excretion unchanged | ~70% |
| Half-life (monotherapy) | ~24 hours (dosing BID) |
| Half-life (with enzyme inducers) | ~12 hours (50% reduction) |
| Clearance | ~25 mL/min |
- Kinetics are linear and not significantly altered by food
- Metabolism: hydroxylation, hydrolysis, glucuronidation - no single metabolite >5% of dose
- Dose adjustment required in moderate-severe renal impairment and hepatic impairment
FDA-Approved Indications
- Epilepsy
- Initial monotherapy in adults and children ≥10 years with partial-onset or primary generalized seizures
- Adjunctive therapy in partial-onset seizures (adults and children ≥2 years)
- Lennox-Gastaut syndrome (adjunctive)
- Primary generalized tonic-clonic seizures
- Migraine prophylaxis (adults)
Off-label uses: Obesity/weight loss, binge eating disorder, bulimia nervosa, alcohol dependence, bipolar disorder (evidence limited), smoking cessation in alcohol-dependent patients.
Dosing
- Start low and titrate slowly (typically 25-50 mg/week increases) to reduce cognitive side effects
- Target doses: epilepsy 200-400 mg/day in 2 divided doses; migraine prophylaxis 100 mg/day
- Pediatric dosing: 5-9 mg/kg/day
Adverse Effects
Common:
- Paresthesia (very common - carbonic anhydrase effect)
- Weight loss / anorexia
- Somnolence, fatigue, dizziness
- Psychomotor slowing ("word-finding difficulties," cognitive slowing)
- Memory and concentration problems
- Taste perversion (carbonated beverages taste flat - classic complaint)
- Nausea, upper respiratory infections
Serious/Important Warnings:
| Adverse Effect | Mechanism/Note |
|---|---|
| Cognitive/neuropsychiatric effects | Confusion, psychomotor slowing, memory problems, depression - most common reason for discontinuation |
| Metabolic acidosis | Hyperchloremic, non-anion gap - dose-dependent; monitor serum bicarbonate at baseline and periodically |
| Nephrolithiasis | ~1.5% of adults; decreased urinary citrate + increased urinary pH due to carbonic anhydrase inhibition; adequate hydration recommended |
| Acute angle-closure glaucoma | Rare; acute onset of eye pain/decreased vision, usually within 1 month; reverse with discontinuation |
| Hyperthermia / decreased sweating | Oligohidrosis; heat-related illness risk, especially in children |
| Suicidality | Class effect with all anticonvulsants |
| Osteomalacia | Related to metabolic acidosis |
| Teratogenicity | Oral cleft risk; Category D in pregnancy |
Drug Interactions
- Enzyme inducers (carbamazepine, phenytoin): nearly double topiramate clearance, reducing half-life ~50%
- Oral contraceptives: topiramate reduces estradiol plasma concentrations - higher OCP doses may be needed
- The renal excretion component is resistant to enzyme inhibitors; only the hepatic fraction is affected
Contraindications / Special Populations
- Renal impairment: clearance reduced ~50% in moderate-severe impairment - dose reduction required
- Hepatic impairment: reduced clearance - dosage adjustment needed
- Pregnancy: associated with oral clefts and small-for-gestational-age infants; use only if benefits outweigh risks
- Gradual withdrawal: abrupt discontinuation increases seizure risk in epileptic patients
Overdose
Acute overdose presents with: convulsions, drowsiness, speech disturbance, blurred vision, diplopia, impaired mentation, somnolence, vertigo, agitation, and mydriasis. Status epilepticus has been reported.
Sources:
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Chapter 33.10
- Goodman & Gilman's Pharmacological Basis of Therapeutics, Chapter 16
This is a shared conversation. Sign in to Orris to start your own chat.